Michael Kranda has over 40 years of pharmaceutical and biotech senior leadership and board oversight experience across a range of public, private and non-profit organizations. Most recently, Michael was CEO of LifeSprout, a Johns Hopkins Institute for NanoBioTechnology spin-out focused on tissue engineering and regenerative medicine. Previously Michael served as Askbio’s Head of CNS Gene Therapy and Head of Corporate Alliance Management where he led the integration of two CNS acquisitions, managed their Parkinson’s, multiple system atrophy, Huntington’s, and Alzheimer’s disease activities, and was on Askbio’s senior leadership team managing its $4 billion acquisition by Bayer. Prior to joining Askbio, Michael was the Director of Business Development at the Allen Institute for Brain Science where he negotiated multiple CNS gene therapy licenses. Michael was also Managing Director at Vulcan Ventures LLC. As CEO of Oxford GlycoSciences (OGS) he closed collaborations with Pfizer, GSK and Bayer and then led OGS through its IPO. Prior to that Michael was President and COO of Immunex (now Amgen).
Menu